Pfizer and BioNTech Halt COVID Vaccine Study Due to Low Enrollment as Vaccine Debate Continues

Pfizer and BioNTech are suspending a government-ordered post-marketing study for their COVID-19 vaccine due to lower-than-expected enrollment, driven by a slow season of COVID cases and declining public interest in vaccination.

The trial, which aimed to enroll 25,500 participants aged 50 to 64 to evaluate vaccine effectiveness against placebo, could not generate relevant data due to recruitment struggles. The companies emphasized the pause is not related to any safety or benefit-risk concerns.

The study was tied to a post-marketing commitment that FDA Commissioner Martin Makary implemented last year for all approved COVID vaccines, requiring placebo-controlled trials — an unusual design when effective vaccines already exist.

The decision reflects broader challenges facing COVID vaccine developers. The CDC has limited the shot's recommended use under HHS Secretary Robert F. Kennedy Jr., who ended routine recommendations for healthy children and pregnant people. Meanwhile, Moderna has pulled back on late-stage vaccine trials and shifted focus toward oncology assets.

Despite billions of vaccinations worldwide confirming safety, continued political attacks on COVID vaccines have contributed to declining uptake. Pfizer and BioNTech have not disclosed next steps for the study.